ClinicalTrials.gg
Drug

Tisotumab vedotin clinical trials

Also written TIVDAK.

studies test it
12
open now
2
in phase 3
1
first study started
2013

How each study uses tisotumab vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tisotumab vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Sept 2021 · TIVDAK · BLA 761208 (FDA, Drugs@FDA)
European Union
28 Mar 2025 · Tivdak · EMEA/H/C/005363 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

tisotumab vedotin
9
Tisotumab Vedotin (HuMax-TF-ADC)
2

Brand

TIVDAK
9

Development codes

PF-08046057
1

Studies by the year they started

12 studies that test it; most in 2019 (3)

Studies that test tisotumab vedotin, by start year
YearStudies
20131
20151
20171
20182
20193
20211
20231
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
9
Phase 3
1
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 1

Seagen Inc. (5) · Seagen, a wholly owned subsidiary of Pfizer (3) · Zai Lab (Shanghai) Co., Ltd. (1) · Genmab (1) · GOG Foundation (1) · Pfizer (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Tisotumab vedotin is the comparator. A study of two new drugs counts under both.

Studies

Open first, then newest update. How each study uses tisotumab vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 12

As the comparator · 1 — what is tested is compared with tisotumab vedotin

Codes

What other systems call tisotumab vedotin · ClinicalTrials.gg INT001329

  • MeSH (NLM) C000707142tisotumab vedotinConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) T41737F88ATISOTUMAB VEDOTINConfirmed FDA, NLM, Wikidata
  • RxNorm 2571094One source FDA
  • Wikidata Q108670929tisotumab vedotinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C113164Tisotumab VedotinOne source FDA
  • DrugBank DB16732One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.